Marapharm Raises $563,500 in the Second Tranche of a Non-Brokered Private Placement Which is in Addition to the $528,000
Raised in the First Tranche for a Total Amount Raised Of $1,091,500. The Private Placement is Oversubscribed and Is
Now Closed.
Kelowna, British Columbia (FSCwire) - (CSE:MDM, FSE:2M0,
OTCQB:MRPHF) – Marapharm Ventures Inc. (“Marapharm” or the “Company”) (http://www.marapharm.com/) announces today that in addition to the completion of
the first tranche of the private placement announced February 29, 2016 the second tranche has also been completed. The Company
has raised CDN$1,091,500 and will issue 5,457,500 units. Each Unit will consist of one common share and one common share
purchase warrant and both are subject to a statutory 4 month hold period from the date of closing. Each whole common share
purchase warrant (“Purchase Warrants”) will entitle the holder to acquire one common share at CDN$0.40. The Purchase Warrants may
be exercised at any time until one year from the closing of the Unit Offering.
The Unit Offering is subject to applicable regulatory requirements and Canadian Securities Exchange (“CSE”)
approval.
The net proceeds raised from the Unit Offering are intended to be used for further development of the Company’s projects and for
working capital. Marapharm will pay cash finder fees of 10% of the gross proceeds raised from subscriptions in the Unit
Offering from persons introduced to the Company by certain eligible Finders. Marapharm will also issue non-transferable common
share purchase warrants (“Finder’s Warrants”) equal to 10% of the number of Units subscribed for by persons introduced to the
Company by eligible Finders. Each Finder’s Warrant will allow the Finder to purchase one additional common share at $0.40 for a
period of one year from the closing of the Unit Offering.
About Marapharm Ventures Inc.
Business information is available at www.marapharm.com and additional
information on the operations or financial results of Marapharm are included in reports on file with applicable securities
regulatory authorities and may be accessed through the CSE website (www.thecse.ca) and Sedar
website (www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
info@marapharm.com
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press
release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Statements
Certain statements contained in this news release constitute forward looking statements. The use of any of the words
“anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are
intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements
are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the
forward-looking statements included in this news release should not be unduly relied upon.
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/marapharm05242016.pdf
Source: Marapharm Ventures Inc. (CSE:MDM, OTCQB:MRPHF)
http://www.marapharm.com/
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2016 Filing Services Canada Inc.
